Antiplatelet and anticoagulant for prevention of reocclusion in patients with atrial fibrillation undergoing endovascular treatment for low extremity ischemia

Yuan, Liangxi; Chen, Cheng; Li, Ziyuan; Zhu, Gang; Bao, Junmin; Zhao, Zhi‐Qing; Lu, Qingsheng; Jing, Zaiping

doi:10.21037/jtd.2018.02.63

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following advantages of rivaroxaban should be noted: no temporary hypercoagulable state, stable anticoagulation effect, fewer drug–food or drug–drug interactions, and less unnecessary INR monitoring to adjust the dose ( 8 , 16 , 17 ). Previous studies have indicated that rivaroxaban affects protease-activated receptors to inhibit cell signalling in atrial myocytes or endothelial cells, thus playing an important role in the pro-inflammatory response to prevent related adverse events ( 8 , 18 ).…”

Section: Discussionmentioning

confidence: 99%

“…In our research, the dose of rivaroxaban administered to the patients was 10 mg per day, and the dose reduction was mainly attributed to the following: (i) The median age of the patients in our cohort was 80.0 years (range, 71.0–84.0 years), which is higher than those in AF registry trials (e.g., 73 years in the ROCKET-AF trial; 71.5 years in the XANTUS trial). (ii) For these patients, renal creatinine clearance probably declines, and the time for rivaroxaban to be metabolised in the body will be prolonged ( 18 , 20 , 21 ). (iii) More importantly, a considerable number of patients in our cohort required single -antiplatelet or dual APT regimens postoperatively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization

Chen

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

IntroductionThe efficacy and safety of antithrombotic strategies remain uncertain in patients with atrial fibrillation undergoing lower-extremity revascularisation.Materials and methodsBetween January 2011 and November 2021, 319 patients with atrial fibrillation after lower-extremity revascularisation received rivaroxaban or warfarin treatment as anticoagulation regimens with different antiplatelet therapy strategies. The primary efficacy outcome was the composite of acute limb ischaemia, major amputation for vascular causes, myocardial infarction, ischaemic stroke, clinically driven target lesion revascularisation, and death from vascular causes. The safety outcomes were major bleeding events according to the International Society on Thrombosis and Haemostasis classification criteria.ResultsA total of 178 and 141 patients received rivaroxaban and warfarin treatments, respectively, after revascularisation with or without antiplatelet regimens. The incidence of the primary efficacy outcome at 36 months in the rivaroxaban group (44 patients, 24.7%) tended to be lower than that in the warfarin group (43 patients, 30.5%) (hazard ratio, 0.870; 95% confidence interval, 0.565–1.339; P = 0.527). The incidence of the secondary efficacy outcomes decreased in the rivaroxaban group (56 patients, 31.6%) compared with that in the warfarin group (61 patients, 43.2%). Major bleeding events occurred in three patients (1.7%) in the rivaroxaban group and five patients (3.5%) in the warfarin group; no significant difference in fatal or intracranial bleeding was observed between the groups.ConclusionThis study describes practical experience regarding the use of rivaroxaban and warfarin in patients with peripheral arterial disease complicated by non-valvular atrial fibrillation following endovascular intervention. The efficacy and safety outcomes do not differ significantly between rivaroxaban and warfarin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization

Chen

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Postoperative anticoagulation was performed accordingly. 9,10,15 The patients with arterial embolism that was resulted from atrial fibrillation, coronary heart disease, rheumatic heart disease, and thoracoabdominal aortic aneurysm, received the following postoperative anticoagulation therapy: low molecular heparin (100 u/kg of injection) after the procedure and oral administration of Warfarin (INR: 2–3) or Rivaroxaban (20 mg per day) after discharge from hospital. The patients with cardiogenic emboli were maintained on long-term anticoagulation with warfarin sodium.…”

Section: Methodsmentioning

confidence: 99%

The effectiveness of percutaneous mechanical thrombectomy in the treatment of acute thromboembolic occlusions of lower extremity

et al. 2020

View full text Add to dashboard Cite

Objectives The objective of this study was to evaluate the effectiveness of percutaneous mechanical thrombectomy as the initial thrombus removal method in the treatment of acute lower extremity ischemia. Methods The patients with acute lower limb ischemia who underwent percutaneous mechanical thrombectomy between August 2016 and February 2018 were retrospectively reviewed. The patients were diagnosed by clinical examination and computed tomography angiography. The percutaneous mechanical thrombectomy was performed as the initial thrombus removal method, followed by anticoagulation therapy. The patients were followed up by clinical examination, imaging, and ankle brachial index (ABI) examination. Results Thirty-two patients (21 males, 11 females; average age of 68.53 ± 8.05; three cases of grade III, 29 cases of grade IIB) were reviewed. Recanalization of the thromboembolic occlusions were achieved in all patients. ABI significantly ( p < 0.01) increased postoperatively (preoperative ABI: 0.51 ± 0.13; postoperative ABI: 0.85 ± 0.65, ABI at three months postoperatively: 0.84 ± 0.66). Eleven patients underwent balloon dilation and three patients had stent placement. Complete thrombus removal was achieved in all patients. The primary patency at 3 months, 6 months, and 12 months postoperatively was 90%, 85%, and 56%, respectively. The secondary patency at 3 months, 6 months, and 12 months postoperatively was 93%, 87%, and 65%, respectively. Conclusions The immediate result appeared to be effective to use percutaneous mechanical thrombectomy as the first thrombus removal method in the treatment of acute thromboembolic occlusions in the lower extremity, while the midterm result needs to be further improved.

show abstract

Aspirin/anticoagulant

2018

Reactions Weekly

View full text Add to dashboard Cite

Antiplatelet and anticoagulant for prevention of reocclusion in patients with atrial fibrillation undergoing endovascular treatment for low extremity ischemia

Abstract: The mono antiplatelet plus anticoagulation therapy offers a safe and effective alternative for prevention of reocclusion in patients with AF undergoing endovascular treatment for lower extremity ischemic.

Cited by 4 publications

References 24 publications

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization

The effectiveness of percutaneous mechanical thrombectomy in the treatment of acute thromboembolic occlusions of lower extremity

Aspirin/anticoagulant

Contact Info

Product

Resources

About